Alzheimer's coverage on Peptide News Digest sits at the intersection of GLP-1 secondary indications and traditional peptide neurology programs. The Phase 3 EVOKE trial of semaglutide in Alzheimer's missed its cognitive endpoint, but a 2026 AAN living systematic review integrating Phase 2/3 trials and real-world data from 2+ million diabetics found GLP-1 use was associated with 20–35% lower dementia incidence versus DPP-4 or SGLT2 inhibitors.
The gap between the EVOKE failure and the registry signals matters. Several follow-on Phase 2 trials are looking at semaglutide in mild cognitive impairment (LIGHT-MCI, OxSENSE), and the broader peptide neurology space has work on neurodegenerative biomarkers and amyloid-related peptide approaches.
Stories here cover trial readouts and the registry data that contextualize them. See #neurodegeneration and #dementia for related threads.
The ELAD trial — a multicenter, randomized, double-blind, placebo-controlled Phase 2b study of liraglutide in 204 mild-to-moderate Alzheimer's disease participants — published in Nature Medicine (online December 2025) continues to drive clinical-research discussions about GLP-1s in neurodegeneration. Coming after the Phase 3 EVOKE trials' negative cognition results, ELAD's intermediate-stage findings are being parsed for endpoints, mechanisms, and biomarker patterns that may guide future trial design in this contested indication.
A comprehensive NeurologyLive review details emerging evidence for GLP-1 receptor agonists across neurological diseases including Alzheimer's, Parkinson's, multiple sclerosis, and stroke. Despite setbacks in the Phase 3 EVOKE Alzheimer's trial, ongoing trials like LIGHT-MCI and OxSENSE continue to explore neurobiological mechanisms beyond metabolic effects.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.